Onyx Pharmaceuticals (ONXX) - Bull of the Day
05 December 2012 - 11:00AM
Zacks
We are upgrading
Onyx Pharmaceuticals (ONXX) to Outperform
based on the company's strong third quarter results and improving
prospects. Onyx reported solid third quarter results with revenues
increasing 19.3% to $89.5 million, well above the Zacks Consensus
Estimate of $81 million.
Third quarter 2012 loss of $0.89 per share was narrower than the
Zacks Consensus Estimate of a loss of $1.08. Recently launched
Kyprolis is off to a solid start and the strong ramp should
continue.
Loss estimates for both 2012 and 2013 have gone down and the
Zacks Rank has moved to #2 (short-term Buy rating) from 3
(short-term Hold rating). With two back-to-back product approvals
to its credit, Onyx has successfully transformed itself from a
one-product company to a multiple-product company.
ONYX PHARMA INC (ONXX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Onyx Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
More Onyx Pharmaceuticals, Inc. (MM) News Articles